Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beta-citronellol is a naturally occurring monoterpene found in cannabis and various essential oils, such as rose and geranium oil. In respiratory research, it has demonstrated significant bronchodilatory effects by relaxing pre-contracted airway smooth muscle (ASM) tissues. The mechanism of action involves the inhibition of myosin light chain 20 (pMLC20) phosphorylation, a key process in muscle contraction. Additionally, beta-citronellol has been shown to work cooperatively with beta-2 adrenergic receptor (B2AR) agonists, such as isoproterenol, to enhance airway relaxation. These findings suggest that beta-citronellol may have therapeutic potential as an adjunct treatment for asthma and other obstructive airway diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta-citronellol.